49.89
-0.21 (-0.42%)
| Penutupan Terdahulu | 50.10 |
| Jumlah Dagangan | 1,642,136 |
| Harga / Pendapatan (P/E Ke hadapan) | 15.45 |
| Harga / Jualan (P/S) | 4.91 |
| Harga / Buku (P/B) | 2.96 |
| Julat 52 Minggu | |
| Hasil Dividen (DY TTM) | 0.64% |
| Margin Keuntungan | 4.68% |
| Margin Operasi (TTM) | 25.89% |
| EPS Cair (TTM) | 0.430 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.40% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 12.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 41.36% |
| Nisbah Semasa (MRQ) | 3.37 |
| Aliran Tunai Operasi (OCF TTM) | 680.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 622.84 M |
| Pulangan Atas Aset (ROA TTM) | 5.75% |
| Pulangan Atas Ekuiti (ROE TTM) | 2.67% |
AISkor Stockmoo
| Nilai 30% | 0.5 |
| Hampir dengan penilaian biasanya. Dikira kurang kerana perolehannya tidak menentu. info | |
| Pulangan di bawah kos modalnya. info | |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai positif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa 30% | 2.2 |
| Tiada aliran jelas sepanjang tahun lalu. Didagangkan hampir paras tertinggi 52 minggu. info | |
| Aliran menaik: harga di atas purata bergeraknya, dan purata itu sedang meningkat. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga naik. info | |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Corak Lilin info | NA |
| Sentimen 20% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Sentimen Pegangan info | NA |
| Sentimen Berita info | NA |
| Wang Pintar 20% | 4.8 |
| Institusi bersih +6.34% daripada saham dalam pemfailan 13F terkini: 218 pemegang menambah, 153 mengurang (suku berakhir 30 Sep 2026). info | |
| Aktiviti Orang Dalam info | NA |
| Keadaan pasaran dan sektor menggalakkan. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor mengatasi prestasi pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Perolehan sesaham turun naik. Perolehan tidak menentu. info | |
| Di atas garis aliran jangka sederhana. info | |
| Harga tinggi berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Aliran naik bagi ketiga-tiga tempoh. Momentum jangka pendek semakin lemah. info | |
| Harga hampir dengan paras rintangan. Paras sokongan dan rintangan menaik. info | |
| Skor Akhir | 2.27 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Qiagen N.V. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| QGEN | - | 0.64% | - | 2.96 | 2.3 |
| RVTY | 17 B | 0.18% | 67.67 | 2.34 | 0.9 |
| CRL | 16 B | - | 356.45 | 4.94 | 0.7 |
| TMO | 248 B | 0.27% | 35.31 | 4.69 | 0.7 |
| DHR | 155 B | 0.67% | 36.48 | 3.00 | 0.4 |
| WAT | 87 B | - | 184.29 | 5.99 | 1.2 |
|
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%). |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.61% |
| % Dimiliki oleh Institusi | 86.26% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 76.28%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 218 | 31,874,519 |
| Berkurang | 153 | 18,912,886 |
| Baharu | 67 | 5,570,055 |
| Dijual habis | 52 | 5,474,496 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Nov 2026 | Yahoo Finance |
Interpreting Qiagen (QGEN) International Revenue Trends
Review Qiagen's (QGEN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock. |
| 11 Nov 2026 | Yahoo Finance |
Qiagen (QGEN) Shareholders Approve Jonathan M Pratt As CEO And Managing Director
Qiagen (NYSE:QGEN) received shareholder approval at an Extraordinary General Meeting for Jonathan M. Pratt to become CEO and Managing Director. Jonathan M. Pratt is set to succeed Thierry Bernard in the top leadership role following the Extraordinary General Meeting vote. The board decision… |
| 06 Nov 2026 | Yahoo Finance |
Qiagen (QGEN) Stock May Be Fully Priced As Sequencing Project Expands
Qiagen has delivered a 35.3% gain over the past three years, and recent headlines around genomics partnerships and sequencing markets keep the story in focus. The question now is whether that share price trajectory lines up with what the company’s cash flows can reasonably support. With a 35.3%… |
| 06 Nov 2026 | Yahoo Finance |
QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director
VENLO, Netherlands, November 06, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN Managing Board at an Extraordinary General Meeting of… |
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |